NRAS and melanoma: To test whether binimetinib plus encorafenib also affected the survival of NRAS-mutant melanoma cells in a more physiological context, tumor tissue excised from two patients with NRAS-mutant melanoma and the established cell line SKMel147 were expanded in a mouse PDX model, and finally, the tumor was removed and prepared for tumor slice cultures.